Repairing resistance

While Novo Nordisk Foundation has funded antimicrobial resistance research for years, the foundation’s investment arm, Novo Holdings A/S, is taking that mandate a step further with its first fund dedicated to early stage venture in the space.

On Wednesday, Novo Holdings’ early venture group Novo Seeds launched the REPAIR Impact Fund with $165 million to invest in biotechs developing therapies for antimicrobial resistance. ...